ATE485296T1 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit - Google Patents

(1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit

Info

Publication number
ATE485296T1
ATE485296T1 AT04752844T AT04752844T ATE485296T1 AT E485296 T1 ATE485296 T1 AT E485296T1 AT 04752844 T AT04752844 T AT 04752844T AT 04752844 T AT04752844 T AT 04752844T AT E485296 T1 ATE485296 T1 AT E485296T1
Authority
AT
Austria
Prior art keywords
pyridinyl
dichloro
analgesic effectiveness
analgesic
effectiveness
Prior art date
Application number
AT04752844T
Other languages
English (en)
Inventor
Michael Buckley
Jianguo Ji
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE485296T1 publication Critical patent/ATE485296T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04752844T 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit ATE485296T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/445,555 US20040242641A1 (en) 2003-05-27 2003-05-27 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
PCT/US2004/015905 WO2004106342A1 (en) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent

Publications (1)

Publication Number Publication Date
ATE485296T1 true ATE485296T1 (de) 2010-11-15

Family

ID=33450880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04752844T ATE485296T1 (de) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit

Country Status (22)

Country Link
US (1) US20040242641A1 (de)
EP (1) EP1626973B1 (de)
JP (1) JP4716999B2 (de)
KR (2) KR20060015738A (de)
CN (1) CN1826344B (de)
AT (1) ATE485296T1 (de)
AU (1) AU2004243270B2 (de)
BR (1) BRPI0410808A (de)
CA (1) CA2526530C (de)
CY (1) CY1111946T1 (de)
DE (1) DE602004029671D1 (de)
DK (1) DK1626973T3 (de)
ES (1) ES2352199T3 (de)
HK (1) HK1092135A1 (de)
MX (1) MXPA05012738A (de)
NZ (2) NZ588123A (de)
PL (1) PL1626973T3 (de)
PT (1) PT1626973E (de)
SI (1) SI1626973T1 (de)
TW (1) TWI332502B (de)
WO (1) WO2004106342A1 (de)
ZA (1) ZA200509601B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (de) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotid kodierend für eine neue humane g-proteingekoppelte rezeptor-variante von hm74, hgprbmy74
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7354937B2 (en) * 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8222278B2 (en) * 2008-06-03 2012-07-17 Abbott Laboratories Treatment of attention-deficit/hyperactivity disorder
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
JP5759470B2 (ja) 2009-10-23 2015-08-05 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての二置換オクタヒドロピロロ［３，４−ｃ］ピロール
EP2491034B1 (de) * 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Kondensierte heterocyclische verbindungen als orexinrezeptormodulatoren
WO2011090669A1 (en) * 2010-01-20 2011-07-28 Abbott Laboratories Methods for treating pain
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
KR102559922B1 (ko) 2016-03-10 2023-07-25 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
EP1147112B1 (de) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyloderivate als nikotin-acetylcholin-rezeptorliganden
CN1348449A (zh) * 1999-04-26 2002-05-08 神经研究公司 杂芳基二氮杂环烷烃及其制备方法和应用
HU225894B1 (en) * 1999-05-21 2007-12-28 Abbott Lab Heterocyclic substituted aminoazacycles useful as central nervous system agents
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents

Also Published As

Publication number Publication date
NZ588123A (en) 2012-04-27
JP2007500220A (ja) 2007-01-11
ZA200509601B (en) 2006-10-25
CY1111946T1 (el) 2015-11-04
CA2526530A1 (en) 2004-12-09
AU2004243270A1 (en) 2004-12-09
BRPI0410808A (pt) 2006-06-27
KR20060015738A (ko) 2006-02-20
CN1826344B (zh) 2013-03-06
AU2004243270B2 (en) 2009-12-17
DK1626973T3 (da) 2011-01-10
KR101238281B1 (ko) 2013-03-04
SI1626973T1 (sl) 2011-01-31
DE602004029671D1 (de) 2010-12-02
CA2526530C (en) 2013-01-08
US20040242641A1 (en) 2004-12-02
JP4716999B2 (ja) 2011-07-06
TWI332502B (en) 2010-11-01
KR20120014235A (ko) 2012-02-16
EP1626973B1 (de) 2010-10-20
HK1092135A1 (en) 2007-02-02
ES2352199T3 (es) 2011-02-16
WO2004106342A1 (en) 2004-12-09
NZ543615A (en) 2009-04-30
MXPA05012738A (es) 2006-02-22
TW200510420A (en) 2005-03-16
PL1626973T3 (pl) 2011-04-29
EP1626973A1 (de) 2006-02-22
CN1826344A (zh) 2006-08-30
PT1626973E (pt) 2010-12-31

Similar Documents

Publication Publication Date Title
CY1111946T1 (el) To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
MY133667A (en) Quinazoline ditosylate salt compounds
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
WO2005107726A3 (en) Method for the treatment of back pain
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2002066500A3 (de) ANTAGONISTEN FÜR Α4β7-INTEGRIN
WO2005023302A3 (en) Anti-cd20 therapy of ocular disorders
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
TW200616631A (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
ATE286883T1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
AU4910500A (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
NO20042846L (no) Derivater av 5-(pyridin-3-yl)-1-azabicyklo[3.2.1]oktan, fremstilling derav og anvendelse av de samme som terapeutiske midler
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
MY142646A (en) Chemokine receptor antagonists and methods of use therefor
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ITMI20030972A1 (it) Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1626973

Country of ref document: EP